A Phase 2 investigator-sponsored neoadjuvant study which will evaluate darolutamide compared to EPI-7386 + darolutamide in patients undergoing prostatectomy for high-risk localized prostate cancer
Latest Information Update: 07 Nov 2024
At a glance
- Drugs Darolutamide (Primary) ; Masofaniten (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- 31 Oct 2024 According to an ESSA Pharma media release, clinical studies with masofaniten including the combination study with abiraterone acetate and apalutamide as well as the remaining investigator sponsored trials will be terminated and the IND and CTAs in different geographies will be withdrawn.
- 31 Oct 2024 According to ESSA Pharma media release, Status changed from planning to discontinued.
- 04 Aug 2022 According to ESSA Pharma media release, this study is planned to be initiated by year end